Melanoma--an unlikely poster child for personal... [N Engl J Med. 2010] - PubMed

loading

Been there, not done that--melanoma in the age of molecular therapy. [N Engl J Med. 2011]
Been there, not done that--melanoma in the age of molecular therapy.
Ernstoff MS. N Engl J Med. 2011 Jun 30; 364(26):2547-8. Epub 2011 Jun 5.
Resistance to BRAF inhibition in melanomas. [N Engl J Med. 2011]
Resistance to BRAF inhibition in melanomas.
Solit DB, Rosen N. N Engl J Med. 2011 Feb 24; 364(8):772-4.
Vemurafenib. [Nat Rev Drug Discov. 2011]
Vemurafenib.
Flaherty KT, Yasothan U, Kirkpatrick P. Nat Rev Drug Discov. 2011 Oct 31; 10(11):811-2. Epub 2011 Oct 31.
Review Vemurafenib: the road to personalized medicine in melanoma. [Drugs Today (Barc). 2012]
Review Vemurafenib: the road to personalized medicine in melanoma.
Amaria RN, Lewis KD, Jimeno A. Drugs Today (Barc). 2012 Feb; 48(2):109-18.
Review PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. [Curr Opin Investig Drugs. 2010]
Review PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Smalley KS. Curr Opin Investig Drugs. 2010 Jun; 11(6):699-706.

Review Mechanisms of resistance to RAF inhibitors in melanoma. [J Invest Dermatol. 2011]
Review Mechanisms of resistance to RAF inhibitors in melanoma.
Aplin AE, Kaplan FM, Shao Y. J Invest Dermatol. 2011 Sep; 131(9):1817-20. Epub 2011 May 19.
Review Molecular profiling of melanoma and the evolution of patient-specific therapy. [Semin Oncol. 2011]
Review Molecular profiling of melanoma and the evolution of patient-specific therapy.
Gajewski TF. Semin Oncol. 2011 Apr; 38(2):236-42.
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. [Cancer Res. 2011]
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al. Cancer Res. 2011 Apr 1; 71(7):2750-60. Epub 2011 Feb 11.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Melanoma--an unlikely poster child for personalized cancer therapy.
Melanoma--an unlikely poster child for personalized cancer therapy.
N Engl J Med. 2010 Aug 26 ;363(9):876-8.

PubMed
Obstructive sleep apnea syndrome and fatty liver: association or causal link?
Obstructive sleep apnea syndrome and fatty liver: association or causal link?
World J Gastroenterol. 2010 Sep 14 ;16(34):4243-52.

PubMed
[Asthenopia and monitor characteristics].
[Asthenopia and monitor characteristics].
J Fr Ophtalmol. 1990 ;13(8-9):456-60.

PubMed
"Human non-subjects research": privacy and compliance.
"Human non-subjects research": privacy and compliance.
Am J Bioeth. 2010 Sep ;10(9):15-7.

PubMed
Numb activates the E3 ligase Itch to control Gli1 function through a novel degra...
Numb activates the E3 ligase Itch to control Gli1 function through a novel degradation signal.
Oncogene. 2011 Jan 6 ;30(1):65-76. Epub 2010 Sep 6 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed